Biotage Launches Accelerated Chromatographic Isolation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biotage Launches Accelerated Chromatographic Isolation


Biotage, a supplier of solutions and technology for analytical, medicinal and peptide chemistry, has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.

According to Biotage, ACI has the potential to improve chromatography efficiency in the laboratory. ACI can move users to the endpoint faster. Traditional purification takes more than 15 minutes. With ACI, the time is reduced to 5 minutes. A 250-mg scale laboratory experiment can now be purified in less than 3 minutes on a 10 g column with an ACI enabled Biotage Isolera flash purification system.

"Chemists will now have freedom to work on other things while they let their ACI system do the purification. It is fully automated, reliable and lightning fast, we can completely purify 250 mg of sample in less than 3 minutes, this is quicker than most people take to run the TLC," said Sunil Rana, global product manager, Biotage, in a press release.

Biotage Isolera systems recommend cartridges based on the sample size and programed TLC data; they work out the best solvent gradient based on compound, and provide real time indication of eluting compounds, using UV, ELSD or mass detection. They subtract signal baselines automatically so that chemists can be confident that the correct fractions are collected.

ACI works seamlessly with the Biotage Isolera system. The simple wizard quickly guides chemists through the system, beneficial for new users or those whose expertise or priorities lie in synthesis rather than purification. Existing Biotage Isolera systems can be upgraded to ACI systems. ACI will come as standard on all new production systems.

Source: Biotage

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here